Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. High-intensity training in patients with spinal and bulbar muscular atrophy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Congenital myopathies are mainly associated with a mild cardiac phenotype

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Guillain-Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Peripheral neuropathy in hereditary spastic paraplegia caused by REEP1 variants

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Illegal cannabis use is common among Danes with multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Patients with multiple sclerosis who experience disease breakthrough often switch disease-modifying therapy (DMT).

OBJECTIVE: To compare treatment effectiveness of switch to highly effective DMT (heDMT) with switch to moderately effective DMT (meDMT) for patients who switch due to disease breakthrough defined as at least one relapse within 12 months of their treatment switch.

METHODS: We retrieved data from The Danish Multiple Sclerosis Registry on all relapsing-remitting MS patients with expanded disability status scale (EDSS) less than 6 who experienced disease breakthrough. We used propensity score matching to compare annualized relapse rates (ARRs), time to first confirmed relapse, time to first confirmed EDSS worsening and time to first confirmed EDSS improvement.

RESULTS: Each matched group comprised 404 patients. Median follow-up time was 3.2 years [interquartile range (IQR) 1.7-5.8]. ARRs were 0.22 (0.19-0.27) with heDMT and 0.32 (IQR 0.28-0.37) with meDMT; relapse rate ratio was 0.70 (95% CI 0.56-0.86; p = 0.001). Escalation to heDMT reduced the hazard of reaching a first relapse (HR 0.65; 95% CI 0.53-0.80; p < 0.001). We found no evidence of delayed disability worsening (HR 0.83; 95% CI 0.62-1.10; p = 0.20) and weak evidence of disability improvement (HR 1.33; 95% CI 1.00-1.76; p = 0.05) with heDMT.

CONCLUSION: Switching to heDMT is associated with reduced ARR and delay of first relapse compared with switching to meDMT. Patients on DMT who experience relapses should escalate therapy to heDMT.

Original languageEnglish
JournalJournal of Neurology
Volume266
Issue number2
Pages (from-to)306-315
Number of pages10
ISSN0340-5354
DOIs
Publication statusPublished - 2019

ID: 56665638